Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeCOVID-19 ImpactImpact of
COVID-19Uncovering the Burden of DiseaseCOVID-19 & Flu ImpactSelect UMCs & Risk FactorsAbout COMIRNATYAbout COMIRNATYIntroductionmRNA TechnologyCOMIRNATY Clinical Trial OverviewCOMIRNATY Pivotal TrialSelect Safety DataRWEReal-World EvidenceRCTs and RWE Considerations24-25 Appaneal Study Design24-25 Appaneal VE AnalysisDosingPatient ProfilesPatient
ProfilesHypothetical Patient ProfilesSusan is 68 years oldClaire has chronic kidney diseaseMike has asthmaHypothetical Patient ProfilesSusan is 68 years oldClaire has chronic kidney diseaseMike has asthmaMaria has coronary artery diseaseTom has type 2 diabetesMaria has coronary artery diseaseTom has type 2 diabetesHypothetical Patient ProfilesSusan is 68 years oldMike has asthmaMaria has coronary artery diseaseTom has type 2 diabetesResourcesResourcesLinks & SupportCOMIRNATY Health Plan CoverageMaterialsHypothetical Patient ProfilesSusan is 68 years oldMike has asthmaMaria has coronary artery diseaseTom has type 2 diabetes
IndicationPrescribing InformationPatient InformationPatient SiteOrder on Pfizer PrimePediatric Information (5 years & older)
Hypothetical Patient ProfilesClaire is 52 years old and has chronic kidney disease.Claire stays busy at work and at home.Claire stays busy at work and at home.She's a community leader with two teenagers to keep her on her toes. She prioritizes staying up to date with COVID-19 vaccinations every year. Your recommendation matters.1According to the CDC, Claire's chronic kidney disease puts her at higher risk for severe outcomes from COVID-19.2*ReferencesThe United States Centers for Disease Control and Prevention (CDC) defines severe outcomes of COVID-19 as hospitalization, admission to the intensive care unit (ICU), intubation or mechanical ventilation, or death.2Risk of experiencing severe outcomes from COVID-19

Individuals with certain underlying medical conditions, including chronic kidney disease, are at a higher risk of experiencing severe outcomes from COVID-19.2

The CDC recognizes chronic kidney disease and receiving dialysis as factors that increase a person's risk of experiencing severe outcomes from COVID-19.2

To learn more about certain underlying medical conditions that increase the risk for experiencing severe outcomes from COVID-19, visit cdc.gov

This website is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.CDC recommendation

The CDC considers chronic kidney disease an underlying medical condition that increases a patient’s risk of severe outcomes2

The CDC recommends a 2025-2026 Formula COVID-19 vaccination using individual-based decision-making7,9†

To learn more about certain underlying medical conditions that increase the risk for experiencing severe outcomes from COVID-19, visit cdc.gov



This website is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.

†Also known as shared clinical decision-making.9Why your recommendation matters to patients like ClaireAccording to the CDC: Many eligible adults may not be aware of which vaccines they are eligible for4

A healthcare professional’s recommendation can be a strong predictor of whether a patient gets vaccinated4

Research suggests that when patients are given a vaccine recommendation and are offered a vaccine at the same time, they are more likely to get vaccinated4

According to the CDC, healthcare providers should review every patient’s immunization history at each appointment to assess for needed vaccines. Providers may coadminister a COVID-19 vaccine and other vaccines for eligible individuals like Claire, if no contraindications exist.5,6‡

‡There are additional considerations for simultaneous administration of an orthopoxvirus vaccine and COVID-19 vaccine. For best practices for administering multiple injections, see CDC Interim Clinical Considerations.5Help protect eligible individuals against severe outcomes from COVID-19 with COMIRNATY7,8 < Back Susan, 68 years oldLoading
Up next >
 Mike, 35 years old, asthmaLoadingReferences:For health care providers. US Department of Health and Human Services. Updated February 20, 2025. Accessed February 10, 2026. https://www.hhs.gov/risk-less-do-more/for-health-care-providers/index.htmlUnderlying conditions and the higher risk for severe COVID-19. Centers for Disease Control and Prevention. Updated February 6, 2025. Accessed February 10, 2026. https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.htmlCOVID-NET interactive dashboard. Centers for Disease Control and Prevention. Accessed January 27, 2026. 
https://www.cdc.gov/covid/php/covid-net/index.htmlAdult immunization standards. Centers for Disease Control and Prevention. Updated August 9, 2024. Accessed February 10, 2026. https://www.cdc.gov/vaccines-adults/hcp/imz-standards/index.htmlInterim clinical considerations for use of COVID-19 vaccines in the United States. Centers for Disease Control and Prevention. Updated November 4, 2025. Accessed February 10, 2026. https://www.cdc.gov/covid/hcp/vaccine-considerations/index.htmlVaccine administration: before giving vaccine. Centers for Disease Control and Prevention. Updated July 10, 2025. Accessed February 10, 2026.  https://www.cdc.gov/vaccines/hcp/administration/before.htmlStaying up to date with COVID-19 vaccines. Centers for Disease Control and Prevention. Updated November 19, 2025. Accessed February 10, 2026. https://www.cdc.gov/covid/vaccines/stay-up-to-date.htmlCOMIRNATY® (COVID-19 Vaccine, mRNA). Prescribing Information. BioNTech Manufacturing GmbH and Pfizer Inc.; August 27, 2025.Recommended adult immunization schedule for ages 19 years or older. Centers for Disease Control and Prevention. Updated October 7, 2025. Accessed February 10, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/adult/adult-combined-schedule.pdfPatient Profiles Downloadable MaterialsLoading

Manufactured for
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz, Germany
Marketing Authorization Holder 

Manufactured by
Pfizer Inc.
New York, NY 10001

The formulation of COMIRNATY, which is based on BioNTech proprietary mRNA technology, was developed by BioNTech and Pfizer.  

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-CVV-USA-5677
You are now leaving PfizerPro

You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COMIRNATY is approved for use in individuals who are:
• 65 years of age and older, or
• 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
Important Safety InformationDo not administer COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.Management of Acute Allergic ReactionsAppropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

Myocarditis and Pericarditis

Postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.

SyncopeSyncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.Altered ImmunocompetenceImmunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.Limitation of Vaccine EffectivenessCOMIRNATY may not protect all vaccine recipients.Adverse ReactionsMost commonly reported adverse reactions after a dose:
  • 12 years of age and older (≥10%) were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).
  • 5 years through 11 years of age (≥5%) were pain at the injection site (up to 83.8%), fatigue (up to 51.9%), headache (up to 38.4%), injection site redness (up to 25.9%), injection site swelling (up to 20%), muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%).
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985
or https:/www.pfizersafetyreporting.com or VAERS at 1-800-822-7967 or https://vaers.hhs.govPlease click for COMIRNATY Full Prescribing Information and Patient Information. Indication
COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COMIRNATY is approved for use in individuals who are:
• 65 years of age and older, or
• 5 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.